It's Time For a Quick Look at Johnson & Johnson (JNJ)'s Fundamentals

Large-cap health care company Johnson & Johnson has moved -0.3% this afternoon, reaching $152.29 per share. In contrast, the average analyst target price for the stock is $179.1.

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company is based in the United States. Johnson & Johnson currently returns an annual dividend yield of 3.0%.

Make Sure to Consider the Following Before Buying Johnson & Johnson:

  • Johnson & Johnson has moved -7.0% over the last year.

  • JNJ has a forward P/E ratio of 14.0 based on its EPS guidance of 10.84.

  • Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 55.8%.

  • The company has a price to earnings growth (PEG) ratio of 2.91.

  • Its Price to Book (P/B) ratio is 5.27

Johnson & Johnson Has Irregular Cash Flows

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023-02-16 21,194,000 -3,466,000 24,660,000 -6.42
2022-02-17 23,410,000 -2,941,000 26,351,000 -0.85
2021-02-22 23,536,000 -3,042,000 26,578,000 12.39
2020-02-18 23,416,000 -233,000 23,649,000 4.33
2019-02-20 22,201,000 -467,000 22,668,000 0.73
2018-02-21 21,056,000 -1,447,000 22,503,000

Johnson & Johnson's free cash flows have a decent average of $24.4 Billion over the last 6 years, but they are highly variable since their coefficient of variability is 104706446633.7%. The compounded average growth rate over this period is 0.0%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.